|
GENOUS™
OPTIMIZING CANCER TREATMENT FOR VIETNAMESE
The right drug. The first time. Everytime
An overview of cancer situation in Vietnam 2022
Number of new cases
180.840
Number of deaths
120.180
Total number of current cancer cases (5 years)
409.144
WE ARE..
Genomate (full name is Genomate Heatlh) is a company based in Cambridge, Massachusetts (USA).Genomate focuses on building a powerful computational model to exploit widely published scientific evidence, along with making the most of clinical experiences enhanced by computational reasoning.All of these allow Genomate to create treatment under the guidance of artificial intelligence (AI), based on unique (unic) characteristics in each patient.
Digosys is a company headquartered in Hanoi.
Digosys's vision by 2030 will become the market leader in providing AI-application diagnostic and treatment services, and integrate these into the routine care process in specialized hospitals.Digosys strives to build trusted partnerships with Start-up companies that have a breakthrough technology platform in the medical field, aiming to provide feasible, effective and economical solutions for cancer, cardiovascular patients... in Vietnam.
STEPS TO PROVIDE SERVICES FOR VIETNAMESE CANCER PATIENTS
_edited.png)
Target/immunity regimen optimization service designed specifically for Vietnamese cancer patients
Obtain the correct unique characteristics in the patient's molecular profile.
Recommend the correct targeted/immune treatment regimen
At the right time, the patient can adapt best
.png)
Take tissue biopsy and/or liquid biopsy samples
Implementation location:
___
Hospitals in Vietnam where patients are treated
STEP 0
Cancer genome sequencing with 511 genes
Implementation location:
___
Datar Cancer Genetics
(UK)
STEP 1
Gene - Target - Drug network analysis and AEL scoring
Implementation location:
___
Genomate
(USA)
STEP 2
Discuss at multifield molecular tumor council (clinical,biology, pharma...)
Implementation location:
___
Online connection between North America, EU and Asia
STEP 3
Delivery Genous™ report to patients and their doctors
Implementation location:
___
Digosys H.Q
STEP 4
DATABASE AND TECHNOLOGY OF GENOUS™
GENE NETWORK - TARGET - DRUG
Based on Genomate's AI drug prescription system, it focuses on accurately selecting the most important goals to be treated, thereby ranking the most optimal and most effective treatment regimens to improve the pathological condition of patients. This process takes place on the basis of a large amount of standardized managed data, and the model is calculated by the open-box AI system.
Image (a,b) visually depicts the evidence spatial relationship between the regulatory gene (cancer gene) - Treatment target (related to the control gene) - Target agent (target drug/immune drug), in the context of the molecular profile of a breast cancer patient in the SHI- VA01 trial. This image carries 2 messages:
i) using bulk cancer gene tables will find more potential treatment targets;
(ií) each patient has its own complex network of Genes - Targets - Drugs, and cannot be managed in a simple, conventional way.
Figure a. Overall Gene - Target - Drug space
Figure b. Partial evidence correlation in the Gene - Target - Drug space
CLINICALLY PROVEN EFFECTIVENESS
(publicized)
Genomate's excellent technology has validated its usefulness through clinical evidence published in the world's leading prestigious journals, such as Nature in 2021; or the most anticipated scientific conferences in the field of cancer, such as the annual conference of the American Society of Clinical Oncology (ASCO) in 2024. These are also the only clinical effects currently verified for the product line
"Ranking of cancer treatment regimens"
% of patients with improved clinical efficacy
Four-fold increase in the number of patients with tumor response
Treatment not recommended by Genomate
Treatment as recommended by Genomate
Three-fold increase in progression-free survival (PFS) with immunotherapy
% of patients surviving
Progression-free survival (months)
mPFS: Median progression-free survival
AEL: Aggregate Evidence Score for Immunotherapy Regimens
Event probability
Time (month)
H: High score for targeted therapy
L: Low score for targeted therapy
Fourfold increase in progression-free survival (PFS) with targeted therapy
Mrs. Ursula von der Leyen
President of the European Commission (EC)
The President of the European Commission (EC) praised Genomate technology as the "Next Scientific Revolution" in his opening speech at the "Master of Digital" event in 2022.
The American Society of Clinical Oncology's Award for Breakthrough Innovation (about AI)
Prof.Ts Christophe Le Tournerau
Professor of medicine at the University of Paris-Sacley (France), and Dean of Early Clinical Trials at the Curie Institute (France)
Christophe Le Tournerau is the leader of the world's first randomized clinical trial (RCT) research in the field of precision cancer (SHIVA01 test). He said: "With the help of Genomate, we can make decisions based on many parameters and rare changes (in terms of genes), thereby taking the next (treatment) steps to fully implement the correct concept of cancer".
Future Unicorn Award of the European Digital Society
AWARD
PRAISE
MEMBER
Member of CancerX - a public-private cooperation initiative of the White House (USA)
Member of the Precision Medicine Alliance (PMC)
Member of the Digital Medical Association (DiMe)
GENOUS™
SUCCESS STORY
The right drug. The first time. Everytime
On a global scale, cancer brings patients and their families fear, obsession, and even financial exhaustion. Evolutionary mechanisms, sophisticated escape from cancer cell treatments make it one of the most insummissible diseases the world has ever faced. Cancer is like a dark cloud dancing in the sky, obscuring the shining golden sun, and making life lose the joyful scene. In that gloomy picture, it turns out that there are still rays of light for cancer patients.
All thanks to the continuous advances in the field of biomedicine and biomedical technology. New discoveries, new technologies are gradually helping people with cancer feel that it is no longer a nightmare with no way out. Of course, the fight against cancer has never had a pause, but humanity is getting to know it better, and finding more effective "Weapons".
Genomate's artificial intelligence (AI) drug prescription system was born, which has been gradually creating a revolution to promote digital, big data and artificial intelligence in cancer treatment. It helps the implementation of the concept of "Precision Oncology" (Precision Oncology) into practice more fully.
And through the success stories, spreading inspiration of some patients who have applied this solution, we will have more hope for a better future, if unfortunately facing tumors called "CANCER".
Long-term survival after metastatic cancer
Kataline is a middle-aged Hungarian woman who was diagnosed with lung cancer with brain metastases in 2012. At the time, her prognosis was just 3 months. Thanks to analysis by Oncompass (a Hungarian company that shares the DDA platform with Genomate),
Read more
Walking Again: A 24-Year-Old Male with Ewing Sarcoma
The 24-year-old young man has faced a tough battle from "Ewing's Sarcoma", a rare form of bone cancer with high malignancy
Read more
Successful Clinical Trial Participation for a 62-Year-Old with Cervical Carcinom
A 62-year-old woman was diagnosed with large-cell cervical endocrine neuroma, a highly malignant form of cancer.
Read more
A Game-Changer: A 34-Year-Old Athlete’s Battle with Adenoid Cystic Carcinoma (ACC
The 34-year-old athlete, the diagnosis of ACC in the left eye socket is a shock. This rare and aggressive cancer not only threatens his sports career, but also his life, especially when it has spread to the liver and bones.
Successful Clinical Trial Participation for a 62-Year-Old with Cervical Carcinom
At 62, this man’s world was turned upside down when he was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile ducts
New hope for a 43-year-old female patient with HER2 positive breast cancer
A 43-year-old female patient was diagnosed with invasive breast cancer of degree III
Read more
Overcoming adversity: The battle of a young female patient with breast cancer and lung cance
The life of a 33-year-old female patient was turned upside down after she was diagnosed with HER2-positive breast cancer.
Read more
Long-term stability in a 74-year-old woman with stomach cancer
At the age of 74, the fight against stomach cancer of this female patient is extremely difficult. After undergoing radical surgery and adjuvant chemotherapy, her cancer still metastasized
Read more
Read more
A New Lease on Life: A 62-Year-Old Woman’s Fight Against NSCLC
Diagnosed with non-small cell lung cancer (NSCLC) and brain metastasis 12 years ago, the female patient - then 50 years old - faced a frightening prognosis of only 3 months to live.
Targeted Therapy Success in a 44-Year-Old Male with Pilocytic Astrocytom
Diagnosed with pilocytic astrocytoma, a slow-growing brain tumor, a 44-year-old man faced a challenging treatment journey. After surgery, he began the Stupp protocol—a standard regimen of chemotherapy and radiation
Read more
CONTACT
29th floor (East Tower) - Lotte Center, 54 Lieu Giai, Cong Vi Ward, Ba Dinh District, Ha Noi.
(024) 3267 3836